Sanofi has announced plans to ally with the not-for-profit organisation Medicines for Malaria Venture (MMV) on the development of new treatments for the tropical disease.
The three-year research project will be called Orthology Malaria and involves the creation of drug candidates based on Sanofi compounds chosen for their potential efficacy, with proof of concept trials among males to follow.
At each stage of this programme, a joint steering committee will evaluate the project's status in accordance with compound progression criteria devised by MMV.
This comes as part of a wider malaria-focused alliance between the two organisations, which was signed earlier this year.
Dr Elias Zerhouni, president of global research and development at Sanofi, said: "This new partnership will enable us to mobilise each organisation's expertise, resources and know-how to identify novel medicines for malaria patients."
The company's shareholders voted to change its name from Sanofi-aventis to Sanofi this month, a move designed to make the brand simpler and easier to remember and pronounce.